Shares of Gland Pharma experienced a rise of 2.10% during today's session, with the price reaching Rs 1,463.30. This movement is noteworthy for investors tracking the pharmaceutical sector and the NIFTY MIDCAP 150 index, where Gland Pharma is a constituent.
The NIFTY MIDCAP 150 includes Gland Pharma, reflecting its significance among mid-sized companies. Analyzing the company's financial performance can provide context to the stock's behavior. According to Moneycontrol analysis, the sentiment on May 12, 2025, was bearish.
Financial Performance
Recent financial data reveals consistent revenue and net profit figures for Gland Pharma. Here’s a snapshot of the company’s financial performance:
| Heading | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| Revenue (Cr) | 1,097.86 | 1,174.83 | 1,012.02 | 1,062.99 | 1,010.78 |
| Net Profit (Cr) | 276.81 | 321.41 | 222.92 | 281.71 | 295.12 |
| EPS | 16.81 | 19.51 | 13.53 | 17.10 | 17.91 |
Annual Financial Highlights
Gland Pharma's annual performance showcases steady growth in key financial metrics:
| Heading | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue (Cr) | 2,633.24 | 3,462.88 | 4,400.71 | 3,616.53 | 4,167.43 |
| Net Profit (Cr) | 772.86 | 997.01 | 1,212.16 | 775.83 | 1,043.33 |
| EPS | 49.88 | 63.07 | 73.84 | 47.12 | 63.35 |
| BVPS | 235.32 | 360.86 | 435.68 | 482.90 | 546.13 |
| ROE | 21.19 | 16.88 | 16.93 | 9.75 | 11.59 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income Statement Highlights
Analyzing the income statement provides further insights into Gland Pharma's financial health. Key figures include:
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
|---|---|---|---|---|---|
| Sales | 4,167 | 3,616 | 4,400 | 3,462 | 2,633 |
| Other Income | 166 | 240 | 223 | 134 | 139 |
| Total Income | 4,334 | 3,856 | 4,624 | 3,597 | 2,772 |
| Total Expenditure | 2,920 | 2,801 | 3,000 | 2,259 | 1,772 |
| EBIT | 1,413 | 1,055 | 1,624 | 1,338 | 1,000 |
| Interest | 7 | 7 | 5 | 3 | 7 |
| Tax | 362 | 272 | 406 | 337 | 220 |
| Net Profit | 1,043 | 775 | 1,212 | 997 | 772 |
Quarterly Performance
A look at the quarterly numbers provides a more granular view of Gland Pharma's income statement:
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|
| Sales | 1,010 | 1,062 | 1,012 | 1,174 | 1,097 |
| Other Income | 65 | 57 | 48 | 46 | 43 |
| Total Income | 1,075 | 1,120 | 1,060 | 1,221 | 1,141 |
| Total Expenditure | 663 | 740 | 759 | 784 | 768 |
| EBIT | 412 | 379 | 301 | 437 | 372 |
| Interest | 18 | 0 | 0 | 4 | 0 |
| Tax | 99 | 98 | 77 | 111 | 94 |
| Net Profit | 295 | 281 | 222 | 321 | 276 |
Cash Flow
Cash flow details reveal the following trends:
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
|---|---|---|---|---|---|
| Operating Activities | 1,135 | 367 | 791 | 604 | 700 |
| Investing Activities | -2,923 | 1,208 | -1,010 | -1,524 | -766 |
| Financing Activities | -7 | 14 | 34 | 1,238 | -6 |
| Others | 6 | 3 | 3 | 3 | 5 |
| Net Cash Flow | -1,789 | 1,594 | -180 | 322 | -66 |
Balance Sheet
The balance sheet provides an overview of Gland Pharma's assets and liabilities:
| Equities & Liabilities | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Share Capital | 16 | 16 | 16 | 16 | 15 |
| Reserves & Surplus | 8,977 | 7,935 | 7,141 | 5,886 | 3,630 |
| Current Liabilities | 414 | 730 | 581 | 512 | 359 |
| Other Liabilities | 132 | 91 | 94 | 80 | 80 |
| Total Liabilities | 9,541 | 8,773 | 7,834 | 6,496 | 4,086 |
| Assets | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
| Fixed Assets | 1,813 | 1,747 | 1,692 | 1,292 | 1,156 |
| Current Assets | 4,571 | 6,888 | 5,844 | 5,123 | 2,846 |
| Other Assets | 3,156 | 137 | 296 | 80 | 83 |
| Total Assets | 9,541 | 8,773 | 7,834 | 6,496 | 4,086 |
| Other Info | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
| Contingent Liabilities | 100 | 128 | 124 | 219 | 134 |
The movement in Gland Pharma's stock price reflects ongoing market dynamics and company-specific financial performance. Investors are likely weighing these factors as they assess the stock's potential.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
